This bill mandates that health plan companies in Minnesota provide coverage for all medical services and prescription medications approved by the FDA for the treatment or management of dementia. It also requires coverage for diagnostic testing to assess the appropriateness or effectiveness of these treatments. Additionally, the bill prohibits the use of step therapy protocols for dementia-related treatments, ensuring that patients have direct access to the necessary medications without having to try alternative treatments first. The provisions of this section will take effect on January 1, 2026, applying to health plans offered, issued, or renewed after that date.

Furthermore, the bill amends Minnesota Statutes 2024, section 256B.0625, subdivision 13f, to include new requirements regarding prior authorization and step therapy protocols. Specifically, it states that any step therapy requirements must comply with the newly inserted sections 62Q.1841 and 62Q.546. The bill also clarifies that prior authorization or step therapy will not be required for any class of drugs approved for the treatment or prevention of HIV and AIDS. These amendments will also take effect on January 1, 2026.

Statutes affected:
Introduction: 256B.0625